ATMP: From bench to bedside

Scientific progress in cellular and molecular biotechnology and continuous research and innovation has led to the development of novel advanced therapy medicinal products (ATMP), such as somatic cell therapy-, gene therapy- and tissue-engineered medicinal products. However, the translation from pre-clinical research to clinical application in patients is challenging and requires extensive knowledge regarding regulatory issues and the good manufacturing practice (GMP)-compliant production of these ATMP. The mission of the ATMP facility is to support bench-to-bedside development of innovative ATMP-based therapies within the Erasmus MC.

gepubliceerd: 26 april 2017

Deel deze pagina: